CLINICAL TRIALS PROFILE FOR PREDNISOLONE SODIUM PHOSPHATE
✉ Email this page to a colleague
All Clinical Trials for Prednisolone Sodium Phosphate
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT01039103 ↗ | Nanocort in Acute Exacerbation of Relapsing-Remitting Multiple Sclerosis (MS) | Terminated | Galapagos NV | Phase 2 | 2009-12-01 | Patients with an acute exacerbation of Relapsing-Remitting Multiple Sclerosis or with Clinically Isolated Syndrome receive either one single infusion of Nanocort or three daily infusions of SoluMedrol. Main objective is to assess the occurrence of new gadolinium-enhanced T1-weighted lesions at week 8 vs week 1 after treatment. |
| NCT01505088 ↗ | Safety and Efficacy Study of Iontophoretic Dexamethasone Phosphate Ophthalmic Solution to Treat Non-Infectious Anterior Segment Uveitis | Completed | Eyegate Pharmaceuticals, Inc. | Phase 3 | 2011-12-01 | The purpose of this study is to evaluate the safety and efficacy of ocular iontophoresis with dexamethasone phosphate ophthalmic solution EGP-437 using the EyeGate® II Drug Delivery System (EGDS) compared to prednisolone acetate ophthalmic suspension (1%) in patients with non-infectious anterior segment uveitis. |
| NCT01534195 ↗ | Evaluation of the Efficacy of Topical Ophthalmic Steroids in a Modified Conjunctival Allergen Challenge (CAC) Model | Completed | ORA, Inc. | Phase 4 | 2012-01-01 | The purpose of this study is to evaluate the effectiveness of the modified Conjunctival Allergen Challenge (CAC) and observe how the produced allergic inflammation reacts to treatment with a proven ocular anti-inflammatory medication, Prednisolone, assessed by the following measures: - Ocular itching - Conjunctival redness |
| NCT01601106 ↗ | Silencing Inflammatory Activity by Injecting Nanocort in Patients at Risk for Atherosclerotic Disease | Unknown status | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | Phase 1/Phase 2 | 2011-09-01 | Cardiovascular disease(CVD) is the leading cause of morbidity and mortality in developed nations. CVD is primarily caused by atherosclerosis, a systemic disease characterized by lipid deposition in the subendothelial space with a concomitant, low-grade inflammatory reaction.(Fuster, Moreno et al. 2005) To date, most therapeutic interventions aimed at lowering CVD have thus far focused on modulating lipid levels, either lowering LDLc or increasing HDLc levels. Yet, since the introduction of statins 20 years ago, there have been few breakthroughs in the treatment of this disease. A promising strategy to reduce CVD is to directly target inflammation at the level of the vessel wall.(van Leuven, van Wijk et al.; Libby 2002) A potential drawback of anti-inflammatory strategies pertains to the thin line between inhibiting 'inappropriate' inflammation versus inducing immuno-suppression. Therefore, continuous low dosed anti-inflammatory drugs have great potential as novel treatment strategies. In the present project, the investigators propose to inject liposomal glucocorticoids intravenously in patients with an increased risk of atherosclerotic disease aiming to reduce vessel wall inflammation. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Prednisolone Sodium Phosphate
Condition Name
Clinical Trial Locations for Prednisolone Sodium Phosphate
Trials by Country
Clinical Trial Progress for Prednisolone Sodium Phosphate
Clinical Trial Phase
Clinical Trial Sponsors for Prednisolone Sodium Phosphate
Sponsor Name
